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Objectives: The aim of this study was to evaluate the cost-effectiveness of neonatal
screening for phenylketonuria (PKU) and medium-chain acyl-coA dehydrogenase (MCAD)
deficiency using tandem mass spectrometry (tandem MS).
Methods: A systematic review of clinical efficacy evidence and cost-effectiveness
modeling of screening in newborn infants within a UK National Health Service perspective
was performed. Marginal costs, life-years gained, and cost-effectiveness acceptability
curves are presented.
Results: Substituting the use of tandem MS for existing technologies for the screening of
PKU increases costs with no increase in health outcomes. However, the addition of
screening for MCAD deficiency as part of a neonatal screening program for PKU using
tandem MS, with an operational range of 50,000 to 60,000 specimens per system per
year, would result in a mean incremental cost of −£17,298 (−£129,174, £66,434) for each
cohort of 100,000 neonates screened. This cost saving is associated with a mean
incremental gain of 57.3 (28.0, 91.4) life-years.
Conclusions: Cost-effectiveness analysis using economic modeling indicates that
substituting the use of tandem MS for existing technologies for the screening of PKU
alone is not economically justified. However, the addition of screening for MCAD
deficiency as part of a neonatal screening program for PKU using tandem MS would be
economically attractive.
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Inborn errors of metabolism (IEM) are a group of genetic
disorders that can have serious clinical consequences for an
affected neonate or young infant. Whereas the incidence of
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each specific metabolic disorder is rare, their collective im-
portance is deemed to be of considerable public health sig-
nificance (18). If undiagnosed and untreated, these disorders
can cause irreversible mental retardation, physical disability,
neurological damage, and even death (17). The most common
disorders of IEM are phenylketonuria (PKU) and medium
chain acyl-coA dehydrogenase (MCAD) deficiency (15;18).
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In the United Kingdom (UK), PKU and congenital hypothy-
roidism are the only disorders screened for routinely. The
UK screening program for PKU is based on the application
of three standard methods: the Guthrie bacterial inhibition
assay, fluorometry, and chromatography.
Tandem mass spectrometry (tandem MS) has the ability
to detect a much wider range of metabolic disorders than con-
ventional methods (9;15;18). Analysis for these additional
conditions can be undertaken using the same blood spot sam-
ple provided for PKU: no additional specimen collection or
sample preparation is required. Analysis of samples by tan-
dem MS is rapid, can be performed in large batches and,
with automatic sample introduction, processed in 24 hours
(4).
In 1997, two reports were published (15;18) by the UK
National Health Service Research and Development Health
Technology Assessment (NHS R&D HTA) Programme, ex-
amining the case for extending the neonatal screening pro-
gram. These reports were generally favorable to the introduc-
tion of some screening for selected disorders but with caveats.
They placed a high priority on evaluating MCAD deficiency
and recommended further studies on the application of tan-
dem MS to neonatal screening. The failure to fund these
studies left many stakeholders disappointed and frustrated
(8;16;19). However, with the subsequent widespread, inter-
national development and adoption of newborn-screening
programs using tandem MS (11), the NHS R&D HTA Pro-
gramme commissioned an updated review of the evidence.
We conducted an economic modeling exercise synthesizing
evidence on the clinical and cost-effectiveness of neonatal
screening for IEMs using tandem MS compared with con-
ventional screening technologies for a UK neonatal screening
population, first for PKU alone and then for PKU and MCAD
deficiency (14). This study summarizes the key findings of
the HTA review (14).
METHODS
We used probabilistic modeling to estimate the marginal costs
and life-years gained of tandem MS compared with conven-
tional screening. A sequential approach was adopted, the
first stage considered the economic implications of replac-
ing conventional screening technologies with tandem MS
for PKU alone. The second stage then considered the incre-
mental cost-effectiveness of adding a simultaneous screen
for MCAD deficiency alongside the screen for PKU. The
economic viewpoint adopted was that of the UK health-
care system: indirect costs were not included. The pri-
mary outcome measure was expressed in terms of life-years
gained.
Evidence on the diagnostic test characteristics of the
tandem MS were obtained from systematic reviews reported
elsewhere (14;15;18). Diagnostic study types that provided
data on the sensitivity, specificity, or positive predictive value
of neonatal screening using tandem MS for PKU and/or
MCAD deficiency up to June 2003 were included in the re-
views. The model adopted a conservative assumption that the
false-negative rates for PKU were the same for existing and
tandem MS screening modalities (.02 percent of screened
cohort). As the overall false-negative rate was assumed to
be the same for both options, all future treatment costs and
morbidity outcomes were assumed to be the same for both
the existing and new technology. Therefore, all further costs
were excluded from the PKU model. The evidence (14) also
suggests that neonatal screening using tandem MS has pro-
duced no false-negatives so far. However, this was regarded
as potentially overoptimistic; therefore, it is assumed that
tandem MS will generate one false-negative for every one
million samples screened.
Costs for all existing technologies were obtained from a
previous HTA report (15) and revalorized to 2001 using the
Health Services Cost Index. These values were used to obtain
a probabilistic estimate of mean cost per specimen examined
for the current screening program. In a similar manner, a
probabilistic estimate of mean cost per specimen examined
was obtained for tandem MS technology, based on current
capital and operating costs. With relatively high fixed capital
costs, unit costs vary considerably according to the volume of
samples processed by a single system. Therefore, mean cost
estimates were calculated for different operating volumes,
from 20,000 up to a maximum of 80,000 samples annually,
with a range estimate based on 50,000 to 60,000 samples as
a most likely operating volume for a single system.
The parameters used for the PKU model are summarized
in Table 1. Table 2 summarizes the parameters used in assess-
ing the combined screening for PKU and MCAD deficiency.
All future costs were discounted at the (then) appropriate
discount rate of 6 percent and all future life-years gained at
1.5 percent. A monograph published in the HTA series pro-
vides further details on methods and modeling assumptions
(14).
The economics of tandem MS screening at different cost-
effectiveness threshold values (i.e., society’s willingness to
pay for an additional unit of health benefit) are presented
using cost-effectiveness acceptability curves. Monte Carlo
simulation is used to undertake multivariate sensitivity anal-
ysis for uncertainty on all random variables and parameter
assumptions in the model.
RESULTS
The costs of using tandem MS compared with conventional
technologies for PKU screening alone are shown in Table 3,
these results are presented for a cohort of 100,000 neonates
screened and for an operating volume of between 50,000
and 60,000 samples per tandem MS system. It is estimated
that the substitution of tandem MS for the conventional PKU
screening technologies alone would add £54,900 per 100,000
neonates for no additional health gain.
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Table 1. PKU Neonatal Screening Program Using Existing Technology and Tandem MS (Main Models Variables Used)
Variable Base value Model distribution Source
Incidence of PKU 9 per 100,000 Poisson distribution Lord et al., 1999 (10); Pandor et al.,
2004 (14)
False-positive rate
(existing technology)
.050% Triangular (.0%, .05%, 1.7%) Pollitt et al., 1997 (15)
False-negative rate
(existing technology)
.020% Fixed. Insufficient data to calculate a range Pollitt et al., 1997 (15)
False-positive rate
(tandem MS)
.029% Triangular (.022%, .029%, .035%)
Lower and upper bounds based on 95% CIs for
PKU diagnostic study
Zytkovicz et al., 2001 (23)
False-negative rate
(tandem MS)
.020% Fixed. Assume same false-negative rates for
both technologies
Pandor et al., 2004 (14)
Sample collection costs Assumed identical for both technologies. These costs excluded from the comparison
Laboratory cost per
sample (existing
technologies)
£.92 per sample Normal: N (.92, .12) Probabilistic estimate Pollitt et al., 1997 (15) (updated to
2001)
Laboratory cost per
sample (tandem MS)
£1.48 per sample Normal: N (1.48, .1). Probabilistic estimate
Repeat sampling rate (for
inadequate sampling)
This refers to repeat sampling required due to poor quality samples (etc.) and is not due to additional
sampling related to false-positives and confirmation protocols. Assumed identical (1%) for both
technologies
Cost of obtaining a repeat
specimen
£20.15 Lognormal distribution. Costs per home visit Netton et al., 2001 (12)
Confirmation cost per
positive case
£60 Lognormal distribution. Includes estimate of
laboratory test costs, referral, and advice
Current laboratory prices for tests
performed
Treatment costs With false-negatives assumed equal, these costs and effects should be the same
Future health and social
care costs
Mortality/morbidity
PKU, phenylketonuria; MS, mass spectrometry; CI, confidence interval.
The incremental costs of using tandem MS for PKU
screening were then included within the model used to eval-
uate the impact of adding a simultaneous screen for MCAD
deficiency. At an operating volume of 50,000 to 60,000 spec-
imens per year per tandem MS, the mean incremental cost
for PKU plus MCAD deficiency screening for a cohort of
100,000 neonates was −£17,298. This cost saving is also
associated with a mean incremental gain of 57.3 (28.0, 91.4)
life-years per 100,000 neonates screened. Table 3 summa-
rizes the results.
Figure 1 shows the cost-effectiveness acceptability
curves for different operating volumes. As might be expected,
the probability of cost-effectiveness increases at higher op-
erating volumes of a tandem MS system. Operating at a
capacity of between 50,000 to 60,000 samples per system
and at a low threshold value of £1000, the probability that
using tandem MS is cost-effective is .86; at a modest cost-
effectiveness threshold value of £5,000 per life-year gained,
the probability is .99.
DISCUSSION
This assessment indicates that substituting tandem MS for
existing technologies for the screening of PKU alone could
not be justified economically. However, replacing the exist-
ing PKU screening program with a tandem MS-based PKU
plus MCAD deficiency screening program would be eco-
nomically attractive.
For any screening technology false-positive results will
incur additional resource costs and may impose psychologi-
cal “disbenefits” on those affected. This assessment incorpo-
rated uncertainty in the false-positive rate of tandem MS for
MCAD deficiency and additional resource consequences of
these false-positive results.
No data were available at the time to quantify the poten-
tial psychological “disbenefits” associated with false-positive
results. Some information has been published more recently,
but these data are based on a broad range of IEM disorders
and are not confined to MCAD deficiency (20). In addition,
this research also found that parents in newborn screened
groups had significantly lower stress than parents in the clin-
ically identified group. Moreover, our assessment indicates
that the ratio of false-positives to true-positives generated
by tandem MS for MCAD deficiency is approximately 3:1,
markedly less than the 50:1 ratio often quoted but based on
a broad range of IEM conditions. To impact on the results of
this assessment, the negative psychosocial effects that poten-
tially arise from three false-positives would need to be large
enough to offset the long-term quality-of-life effects from ad-
verse outcomes preventable through screening both for the
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Table 2. PKU Screening Using Tandem MS with and without an Additional Screen for MCAD Deficiency (Main Models Variables
Used)
Variable Base value Model distribution Source
Incidence of MCAD
deficiency
8.3 per 100,000 Normal: N (8.3, 2) Pollitt et al., 1997 (15)
False-positive rate for MCAD
deficiency screening
.023% Lognormal: mean, .023% (95% CI,
.0159%–.0297%)
Pandor et al., 2004 (14)
False-negative rate (MCAD
deficiency screening)
.0001% Normal: N (.0001%, .00001%) Assumption
Proportion of cases who
remain asymptomatic
.30 Uniform: U (.25, .35) Pollitt et al., 1997 (15)
Incremental cost of tandem
MS for PKU
£54,900 Derived from previous model
Acute “presentation” episode
cost
£1,043 Lognormal: mean £1043 (95% CI,
£207–£3,292)
Department of Health, 2002 (6)
Proportion of screened cases
who develop significant
disability
.00 Assumed zero. Evidence indicates no appreciable cognitive impairments or
neurological damage due to effectiveness of early treatment (5;21)
Proportion of symptomatic
cases who develop
significant disability
.125 Uniform: U (.10, .15). Note that these
proportions only apply to symptomatic
cases (i.e., incident cases minus the
expected numbers who would remain
asymptomatic in the absence if screening)
Iafolla et al., 1994 (7); Pollitt et al.,
1997 (15); Tanner et al., 2001 (19)
Future health and social care
costs for moderate to severe
disabilities and impairments
£188,500 Uniform: U (£88,000, £290,000). Information derived from two sources (2;10) and
re-worked to represent a range of costs associated with different levels of
disabilities and impairments
Life expectancy (with
significant disability)
55 yr Beta (4, 6, 35, 65) Pandor et al., 2004 (14)
Life expectancy (for
asymptomatic and those
without significant
disability)
75 yr Uniform: U (75, 80). Figures taken from Government Actuaries Department
(GAD) Life Tables for 2001; 75 for males and 80 for females. Assumed normal
life expectancy for those detected and treated before significant impairments
develop; or for those who remain asymptomatic
Mortality proportion in
screened cases
.00 Assumed zero. Evidence (1;3;5;21) indicates no subsequent deaths of diagnosed
cases in recent years based on effectiveness of early treatment
Mortality proportion in
unscreened cases
.20 Uniform: U (.15, .25) Pandor et al., 2004 (14); Pollitt et al.,
1997 (15)
PKU, phenylketonuria; MS, mass spectrometry; MCAD, medium-chain acyl-coA dehydrogenase; CI, confidence interval.
Table 3. Comparison of Costs of Screening for PKU and for PKU Plus MCAD Deficiency Using Existing Technologies and
Tandem MS
Tandem MS Incremental change
Existing methods PKU + MCAD PKU + MCAD
PKU only PKU only deficiency PKU only deficiency
Mean cost of screening and £129,744 £184,644 £112,446 £54,900 (£23,738, −£17,298 (−£129,174,
treatment for 100,000 neonates £86,062) £66,434)
Cost per neonate screened £1.30 £1.85 £1.12 £.55 (£.24, £.86) −£.18 (−£1.29, £.66)
PKU, phenylketonuria; MS, mass spectrometry; MCAD, medium-chain acyl-coA dehydrogenase.
affected child and parents. The balance of these quality-of-
life effects would still appear to favor screening in the case
of MCAD deficiency.
Health benefits within the economic model were ex-
pressed in terms of gains in life-years only. However, the
absence of quality of life weights for MCAD deficiency al-
most certainly underestimates the health benefits of screen-
ing, because no account is taken of reduced quality of
life for those affected by moderate to severe disabilities;
affects mainly avoided by early detection and treatment
afforded by screening. Our model assumes that mortality
in MCAD deficiency cases occurs only in cases present-
ing symptomatically. Studies of screened cohorts consis-
tently have reported no deaths (3) in infants found to have
MCAD deficiency once systems for adequate clinical follow-
up are established (21;22), and no cases of appreciable cogni-
tive impairment or neurological damage have been reported
(5;21).
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Figure 1. Cost-effectiveness acceptability curves for phenylketonuria (PKU) plus medium-chain acyl-coA dehydrogenase
(MCAD) deficiency screening using tandem mass spectrometry (MS) compared with conventional screening for PKU alone.
Laboratory operating volume (specimens per annum). – –, 20,000; --- ---, 40,000; — —, Range 50,000–60,000; – –, 70,000;
– –, 80,000.
At the same time as our review of evidence was under
way, the Department of Health National Screening Commit-
tee commissioned a 5-year pilot study on the clinical and
economic implications of extending neonatal screening of
PKU to include MCAD deficiency using tandem MS (13).
The initial phase of this study has developed screening and
diagnostic protocols, initial clinical management protocols
and patient and health professional information resources.
This study commenced screening in March 2004 and will
continue for 24 months. As part of our modeling work, a
value of information analysis was also performed to quan-
tify the value of additional research to reduce uncertainty
in random variables and parameter assumptions. The results
reported elsewhere (14) show that the single most impor-
tant driver of cost-effectiveness is the level of future dis-
ability costs incurred as a consequence of any neurologi-
cal and cognitive impairments caused by failure to iden-
tify and treat MCAD deficiency cases early and the extent
to which these costs would be avoided through screening
detection.
The economic evidence around screening for other
IEM conditions using tandem MS is far more problem-
atic at present; therefore, no conclusion as to relative cost-
effectiveness could be reached without additional research
(14). Our modeling of the economic evidence provides im-
portant priorities for future research into possible extensions
of neonatal screening using tandem MS. This prioritizing
demonstrates that one of the most important drivers of rela-
tive cost-effectiveness is difference in long-term outcomes;
that is, future disabilities incurred as a consequence of any
neurological and cognitive impairments caused by IEM dis-
orders and the extent to which these effects, and their asso-
ciated costs, can be avoided through the early detection and
treatment afforded by screening.
CONCLUSIONS
In conclusion, the results of our review of the available ev-
idence and modeling of cost-effectiveness indicates that the
introduction of tandem MS into a UK neonatal screening
program for PKU and MCAD deficiency combined would
be economically attractive.
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